Maximillia Wiegand's Podcast

Author: Maximillia Wiegand

Patients that are affected by the disease would no doubt take it despite the high price point and a lack of definitive proof of being effective. The galling part was would this be a precedent for other drug makers to use this route to fast track their approval that was otherwise reserved for a special class of drugs? Hopefully the benefit of the drug really would outweigh the cost.
Be a guest on this podcast

Language: en

Genres: Health & Fitness, Medicine

Contact email: Get it

Feed URL: Get it

iTunes ID: Get it

Get all podcast data